Vivodyne Aims to Address Data Gaps in AI Drug Discovery with Human Tissue Models
Biotech startup Vivodyne is challenging the current state of AI-driven drug discovery by addressing a critical data limitation. The company has developed HIVE, autonomous robotic labs capable of growing and testing human tissue models that generate causal biological data more representative of real-world conditions than animal or cell-based studies. Vivodyne's CEO Andrei Georgescu argues that current AI models lack the necessary depth to accurately predict drug efficacy in humans. Despite high-profile claims from leaders at Anthropic, OpenAI, and DeepMind about curing diseases like cancer with AI, tangible results remain limited. The startup has raised nearly $80 million and recently opened a large-scale lab near San Francisco. The company's approach aims to reduce the failure rate of clinical trials by providing more accurate preclinical data before expensive human testing begins. Vivodyne claims its tissue models achieve high predictive accuracy compared to real human responses, potentially transforming how pharmaceutical companies develop new drugs.
Topics: AI drug discovery biological data limitations Vivodyne HIVE system